Novel Oral Anticoagulants

At Pure Pharma, we manufacture a complete range of Novel Oral Anticoagulants (NOACs) used in the prevention and treatment of thromboembolic disorders. Our NOAC portfolio includes Rivaroxaban, Apixaban, and Dabigatran, offered in various therapeutic strengths and packaging formats.

These oral anticoagulant drugs offer predictable pharmacokinetics and fewer food and drug interactions compared to traditional therapies like warfarin, making them an ideal choice for long-term use in conditions like atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE).

All NOAC medicines are produced at our WHO-GMP- and ISO-certified facility in Abu Dhabi, UAE, ensuring global quality compliance.

Novel Oral Anticoagulants (NOACs) are a new generation of blood-thinning agents used to reduce the risk of stroke, systemic embolism, and venous thromboembolism. Unlike older anticoagulants, NOACs do not require regular INR monitoring and have a more favourable safety profile.

• Atrial Fibrillation (AF)

• Deep Vein Thrombosis (DVT)

• Pulmonary Embolism (PE)

• Post-surgical thromboprophylaxis

All NOACs are formulated using pharma-grade APIs and undergo strict QC testing at our Abu Dhabi-based manufacturing plant.

• 10 mg | 15 mg | 20 mg – Pack of 30's

Used for: DVT, PE, and stroke prevention in atrial fibrillation

Class: Factor Xa Inhibitor

• 2.5 mg | 5 mg – Pack of 30's

Used for: AF-related stroke prevention, DVT/PE treatment

Class: Factor Xa Inhibitor

• 75 mg | 110 mg | 150 mg – Pack of 30's

Used for: Stroke prevention, post-hip replacement thromboprophylaxis

Class: Direct Thrombin Inhibitor

Q: What does NOAC stand for?

A: NOAC stands for Novel Oral Anticoagulant. These are a newer class of blood thinners used to prevent and treat blood clots. Unlike traditional anticoagulants like warfarin, NOACs offer predictable effects, fewer food and drug interactions, and do not require regular INR monitoring.

Q: What conditions are NOACs used for?

A: NOACs are used to prevent blood clots in atrial fibrillation, treat DVT and PE, and prevent post-surgical thrombosis.

Q: How are NOACs different from warfarin?

A: NOACs offer fixed dosing, fewer interactions, and no routine INR monitoring, unlike warfarin.

Q: Are NOACs safe for long-term use?

A: Yes, when prescribed appropriately. They are clinically proven for long-term anticoagulation therapy.

Q: What is the recommended management for pulmonary embolism?

A: Management of pulmonary embolism (PE) typically involves immediate anticoagulation therapy to prevent further clot formation. NOACs such as Rivaroxaban, Apixaban, and Dabigatran are commonly used due to their rapid onset and oral administration. Treatment duration depends on the patient's risk factors and may last from 3 months to lifelong in recurrent cases.

Q: What are the current guidelines for anticoagulation in atrial fibrillation?

A: According to international guidelines (e.g., ESC, AHA/ACC), patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of ≥2 are recommended to receive oral anticoagulation. NOACs are preferred over warfarin in eligible patients due to better safety profiles and fewer monitoring requirements. Apixaban, Rivaroxaban, and Dabigatran are all guideline-approved options.

✔ WHO-GMP Certified Anticoagulant Range

✔ Global Supply Chain Support

✔ 30’s Tablet Packs for Better Compliance

✔ Full Range: Rivaroxaban, Apixaban, Dabigatran

✔ Delivered to Hospitals, Pharmacies, and Government Tenders

All our novel oral anticoagulants (NOACs) are proudly developed and manufactured at our state-of-the-art facility located in Al Ma\`Mourah \- KHIA 8, Abu Dhabi, UAE. As part of our commitment to global standards, Pure Pharmaceutical (PPGH+X76) operates under strict GMP guidelines to ensure the highest level of safety, efficacy, and quality in every product we produce.

📞 Looking to partner with us or request product samples?

Contact our business development team to learn more about availability, pricing, and global shipping.

At Pure Pharma, we are committed to delivering a complete spectrum of high-quality medications across a wide range of therapeutic areas. In addition to our Novel Oral Anticoagulants (NOACs) products, our portfolio includes treatments for infectious diseases, gastrointestinal issues, cardiovascular health, and much more.

If you're seeking treatments beyond allergy relief, we invite you to explore our full range:

• Manage infections effectively with our Anti-Infective medicines.

• Support digestive health through our Gastrointestinal category.

• Discover trusted medications for heart and metabolic disorders in our Cardio-Metabolic range.

• Relieve pain and inflammation with our NSAIDs & Pain Killers.

• Address digestive flare-ups with targeted Anti-Diarrhea therapies.

• Explore safe and effective urological solutions in our Urology category.

• Fight fungal infections with our wide selection of Anti-Fungal medications.

• Enhance wellness with our essential Supplements line.

• Manage neurological conditions with our Anti-Epilepsy products.

• Support fluid balance with our effective Diuretics.

• Treat uric acid buildup and inflammation with our Gout Management therapies.

• Reduce stroke and clotting risks with our Novel Oral Anticoagulants (NOACs).

• Complement pain therapy with our Adjunct Medications for Pain.

• Promote restful sleep naturally with our Sleep Support solutions.

Each of these categories reflects our dedication to quality, efficacy, and patient safety, all manufactured under strict GMP conditions in our Abu Dhabi facility.